Literature DB >> 33463070

Role of miR-466 in mesenchymal stromal cell derived extracellular vesicles treating inoculation pneumonia caused by multidrug-resistant Pseudomonas aeruginosa.

Meng-Meng Shi1,2, Ying-Gang Zhu3, Jia-Yang Yan1,2, Jean-Jacques Rouby4, Hanssa Summah1,2, Antoine Monsel4,5,6, Jie-Ming Qu1,2.   

Abstract

RATIONALE: The effects of mesenchymal stromal cells (MSCs) and MSC-derived extracellular vesicles (MSC EVs) on multidrug-resistant pseudomonas aeruginosa (MDR-PA)-induced pneumonia remain unclear.
MATERIALS AND METHODS: MicroRNA array and RT-PCR were used to select the major microRNA in MSC EVs. Human peripheral blood monocytes were obtained and isolated from qualified patients. The crosstalk between MSCs/MSC EVs and macrophages in vitro was studied. MDR-PA pneumonia models were further established in C57BL/6 mice and MSC EVs or miR-466 overexpressing MSC EVs were intratracheally instilled.
RESULTS: MiR-466 was highly expressed in MSC EVs. MSCs and miR-466 promoted macrophage polarization toward Type 2 phenotype through TIRAP-MyD88-NFκB axis. Moreover, cocultured macrophages with miR-466 overexpressing MSCs significantly increased the phagocytosis of macrophages. MSC EVs significantly reduced mortality and decreased influx of BALF neutrophils, proinflammatory factor levels, protein, and bacterial load in murine MDR-PA pneumonia. Administration of miR-466 overexpressing MSC EVs further alleviated the inflammatory severity.
CONCLUSIONS: MSC-derived EVs containing high levels of miR-466 may partly participate in host immune responses to MDR-PA. Both MSCs and MSC EVs have therapeutic effects in treating MDR-PA-induced pneumonia.
© 2021 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.

Entities:  

Keywords:  extracellular vesicles; mesenchymal stromal cell; micoRNA; multidrug-resistant pseudomonas aeruginosa; pneumonia

Mesh:

Substances:

Year:  2021        PMID: 33463070      PMCID: PMC7805403          DOI: 10.1002/ctm2.287

Source DB:  PubMed          Journal:  Clin Transl Med        ISSN: 2001-1326


  47 in total

1.  Arginase-1 and Ym1 are markers for murine, but not human, alternatively activated myeloid cells.

Authors:  Geert Raes; Rafaël Van den Bergh; Patrick De Baetselier; Gholamreza Hassanzadeh Ghassabeh; Chris Scotton; Massimo Locati; Alberto Mantovani; Silvano Sozzani
Journal:  J Immunol       Date:  2005-06-01       Impact factor: 5.422

Review 2.  Macrophage activation and polarization as an adaptive component of innate immunity.

Authors:  Massimo Locati; Alberto Mantovani; Antonio Sica
Journal:  Adv Immunol       Date:  2013       Impact factor: 3.543

3.  Therapeutic Effects of Human Mesenchymal Stem Cell-derived Microvesicles in Severe Pneumonia in Mice.

Authors:  Antoine Monsel; Ying-gang Zhu; Stephane Gennai; Qi Hao; Shuling Hu; Jean-Jacques Rouby; Michelle Rosenzwajg; Michael A Matthay; Jae W Lee
Journal:  Am J Respir Crit Care Med       Date:  2015-08-01       Impact factor: 21.405

4.  Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.

Authors:  Andre C Kalil; Mark L Metersky; Michael Klompas; John Muscedere; Daniel A Sweeney; Lucy B Palmer; Lena M Napolitano; Naomi P O'Grady; John G Bartlett; Jordi Carratalà; Ali A El Solh; Santiago Ewig; Paul D Fey; Thomas M File; Marcos I Restrepo; Jason A Roberts; Grant W Waterer; Peggy Cruse; Shandra L Knight; Jan L Brozek
Journal:  Clin Infect Dis       Date:  2016-07-14       Impact factor: 9.079

5.  Adipose Tissue-Derived Mesenchymal Stem Cells Attenuate Pulmonary Infection Caused by Pseudomonas aeruginosa via Inhibiting Overproduction of Prostaglandin E2.

Authors:  Yan-Xiong Mao; Jin-Fu Xu; Eric J Seeley; Xiao-Dan Tang; Lu-Lu Xu; Ying-Gang Zhu; Yuan-Lin Song; Jie-Ming Qu
Journal:  Stem Cells       Date:  2015-05-13       Impact factor: 6.277

6.  International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT).

Authors:  Antoni Torres; Michael S Niederman; Jean Chastre; Santiago Ewig; Patricia Fernandez-Vandellos; Hakan Hanberger; Marin Kollef; Gianluigi Li Bassi; Carlos M Luna; Ignacio Martin-Loeches; J Artur Paiva; Robert C Read; David Rigau; Jean François Timsit; Tobias Welte; Richard Wunderink
Journal:  Eur Respir J       Date:  2017-09-10       Impact factor: 16.671

7.  Mesenchymal Stromal Cells Modulate Macrophages in Clinically Relevant Lung Injury Models by Extracellular Vesicle Mitochondrial Transfer.

Authors:  Thomas J Morrison; Megan V Jackson; Erin K Cunningham; Adrien Kissenpfennig; Daniel F McAuley; Cecilia M O'Kane; Anna D Krasnodembskaya
Journal:  Am J Respir Crit Care Med       Date:  2017-11-15       Impact factor: 21.405

8.  An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals.

Authors:  Gustavo Matute-Bello; Gregory Downey; Bethany B Moore; Steve D Groshong; Michael A Matthay; Arthur S Slutsky; Wolfgang M Kuebler
Journal:  Am J Respir Cell Mol Biol       Date:  2011-05       Impact factor: 6.914

9.  Therapeutic effects of human mesenchymal stem cell microvesicles in an ex vivo perfused human lung injured with severe E. coli pneumonia.

Authors:  Jeonghyun Park; Seonguk Kim; Hyungsun Lim; Airan Liu; Shuling Hu; JaeHoon Lee; Hanjing Zhuo; Qi Hao; Michael A Matthay; Jae-W Lee
Journal:  Thorax       Date:  2018-08-03       Impact factor: 9.139

Review 10.  Antimicrobial susceptibility of Pseudomonas aeruginosa in China: a review of two multicentre surveillance programmes, and application of revised CLSI susceptibility breakpoints.

Authors:  Meng Xiao; Yao Wang; Qi-Wen Yang; Xin Fan; Mitchell Brown; Fanrong Kong; Ying-Chun Xu
Journal:  Int J Antimicrob Agents       Date:  2012-08-19       Impact factor: 5.283

View more
  6 in total

Review 1.  MicroRNAs as Regulators of Phagocytosis.

Authors:  Wojciech Gierlikowski; Barbara Gierlikowska
Journal:  Cells       Date:  2022-04-19       Impact factor: 7.666

2.  Preclinical efficacy and clinical safety of clinical-grade nebulized allogenic adipose mesenchymal stromal cells-derived extracellular vesicles.

Authors:  Meng-Meng Shi; Qing-Yuan Yang; Antoine Monsel; Jia-Yang Yan; Cheng-Xiang Dai; Jing-Ya Zhao; Guo-Chao Shi; Min Zhou; Xue-Mei Zhu; Su-Ke Li; Ping Li; Jing Wang; Meng Li; Ji-Gang Lei; Dong Xu; Ying-Gang Zhu; Jie-Ming Qu
Journal:  J Extracell Vesicles       Date:  2021-08-14

Review 3.  Advances in the Regulation of Macrophage Polarization by Mesenchymal Stem Cells and Implications for ALI/ARDS Treatment.

Authors:  Chang Liu; Kun Xiao; Lixin Xie
Journal:  Front Immunol       Date:  2022-07-08       Impact factor: 8.786

Review 4.  The current landscape of microRNAs (miRNAs) in bacterial pneumonia: opportunities and challenges.

Authors:  Fan Zhang; Yunxin Zhou; Junying Ding
Journal:  Cell Mol Biol Lett       Date:  2022-08-19       Impact factor: 8.702

5.  Let-7b-5p in vesicles secreted by human airway cells reduces biofilm formation and increases antibiotic sensitivity of P. aeruginosa.

Authors:  Katja Koeppen; Amanda Nymon; Roxanna Barnaby; Laura Bashor; Zhongyou Li; Thomas H Hampton; Amanda E Liefeld; Fred W Kolling; Ian S LaCroix; Scott A Gerber; Deborah A Hogan; Swetha Kasetty; Carey D Nadell; Bruce A Stanton
Journal:  Proc Natl Acad Sci U S A       Date:  2021-07-13       Impact factor: 11.205

Review 6.  Small extracellular vesicles from menstrual blood-derived mesenchymal stem cells (MenSCs) as a novel therapeutic impetus in regenerative medicine.

Authors:  Lijun Chen; Jingjing Qu; Quanhui Mei; Xin Chen; Yangxin Fang; Lu Chen; Yifei Li; Charlie Xiang
Journal:  Stem Cell Res Ther       Date:  2021-08-03       Impact factor: 6.832

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.